News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VaxInnate Corporation Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu


6/12/2012 10:18:26 AM

CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

Read at BioSpace.com

comments powered by Disqus
   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES